Muntadher Al-Bulanee

Residual cardiovascular risk beyond LDL-cholesterol control: what remains unaddressed?

Statins, ezetimibe, and PCSK9 inhibitors have enabled LDL-cholesterol to be lowered to levels previously thought very hard to achieve. However, even after achieving low levels, some patients continued to have cardiovascular events, a phenomenon known as residual cardiovascular risk. This phenomenon indicates the comple...